- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Economic Burden Associated With Uncomplicated UTIs
Panelists discuss how treatment failure in uncomplicated urinary tract infections (UTIs) creates substantial economic burden through direct costs of additional health care visits, repeated diagnostic tests, and rescue medications alongside indirect costs from productivity losses, with implications including progression to complicated infections such as pyelonephritis, increased emergency department use, antimicrobial resistance development threatening broader public health, psychological impacts on patients, and strain on health care resources that could be mitigated through more effective initial treatment strategies.
EP: 1.Differentiating Uncomplicated and Complicated Urinary Tract Infections (UTIs)
EP: 2.Trends in Uncomplicated UTIs
EP: 3.Exploring Social Determinants of Health in Uncomplicated UTIs
EP: 4.Examining Uncomplicated UTI Recurrence
EP: 5.Role of Patients’ Education in Uncomplicated UTIs
EP: 6.Patient Burden Associated With Uncomplicated UTIs
EP: 7.Minimizing Antibiotic Resistance Development in Uncomplicated UTIs
EP: 8.Examining the Need for Updated Guidelines for Uncomplicated UTIs
EP: 9.Comparing Standard-of-Care Antibiotics for Uncomplicated UTIs
EP: 10.Patient Factors Influencing Antibiotic Selection in Uncomplicated UTIs
EP: 11.Recurrence Rates in Uncomplicated UTIs
EP: 12.Economic Burden Associated With Uncomplicated UTIs
EP: 13.Important Updates in the Management of Uncomplicated UTIs
EP: 14.Exploring Novel Options for the Management of Uncomplicated UTIs
EP: 15.Comparing Newer With Traditional Agents in Uncomplicated UTIs
EP: 16.Payer-Related Barriers With Therapies Used for Uncomplicated UTIs
EP: 17.Final Panel Thoughts on Uncomplicated UTI Management
Video content above is prompted by the following:
- Explain the economic burden of treatment failure in uncomplicated UTI.
- What implications does treatment failure have for patient outcomes and public health?
Lack of CD20 Expression Worsens Outcomes for Bispecifics in R/R DLBCL
July 16th 2025Real-world analysis reveals that undetectable CD20 expression worsens outcomes for patients treated with epcoritamab and glofitamab bispecific antibodies for their diffuse large B-cell lymphoma (DLBCL).
Read More
